CD28 and neoplasm: AKT inhibition or deletion does increases (1) the percentage of CD8+ T cells at the end of REP, (2) cytokine production including IFN‐γ, TNF‐α and GZMB production upon restimulation in response to a‐CD3/a‐CD28, and (3) tumor killing ability of TIL to patient‐derived tumor cells, all promising better anti‐tumor efficacy of TIL in patients.